|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Validus Pharmaceuticals |
|---|---|
| Information provided by: | Validus Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00350857 |
Purpose
To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.
| Condition | Intervention | Phase |
|---|---|---|
|
Bipolar I Disorder |
Drug: Extended-Release Carbamazepine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder. |
| Estimated Enrollment: | 225 |
| Study Start Date: | July 2006 |
| Estimated Study Completion Date: | May 2008 |
Eligibility| Ages Eligible for Study: | 10 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Key Inclusion Criteria:
Exclusion Criteria:
Key Exclusion Criteria:
Contacts and Locations
Show 26 Study Locations
More Information
| Study ID Numbers: | SPD417-311 |
| Study First Received: | July 10, 2006 |
| Last Updated: | October 4, 2007 |
| ClinicalTrials.gov Identifier: | NCT00350857 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Tranquilizing Agents Disease Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Antimanic Agents Pharmacologic Actions Pathologic Processes |
Carbamazepine Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants |